Abstract
Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.
| Original language | English |
|---|---|
| Pages (from-to) | 431-449 |
| Journal | Chromosoma |
| Volume | 122 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2013 |
| MoE publication type | A1 Journal article-refereed |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- anti-mitotics
- cancer
- drug development
- LMW inhibitors
- mitosis
Fingerprint
Dive into the research topics of 'Mitosis as an anti-cancer drug target'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver